Brief: T2 Biosystems Announces Exclusive US Agreement With Cardinal Health To Sell Its FDA-Cleared Direct-From-Blood Diagnostics For Rapid Detection Of Sepsis-Causing Pathogens
07/10/2024 14:22
Oct 7 (Reuters) - Cardinal Health Inc CAH.N :
* T2 BIOSYSTEMS ANNOUNCES EXCLUSIVE U.S. AGREEMENT WITH
CARDINAL
HEALTH TO SELL ITS FDA-CLEARED DIRECT-FROM-BLOOD DIAGNOSTICS FOR
RAPID DETECTION OF SEPSIS-CAUSING PATHOGENS
Source text for Eikon: ID:nGNX4JYWKG
Further company coverage: CAH.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on T2 Biosystems
See all newsBrief: T2 Biosystems Announces Intent To Wind Down Operations
Brief: T2 Biosystems Enters Amendment No. 12 To Term Loan Agreement
Brief: T2 Biosystems Announces Exclusive US Agreement With Cardinal Health To Sell Its FDA-Cleared Direct-From-Blood Diagnostics For Rapid Detection Of Sepsis-Causing Pathogens
T2 Biosystems Inc reports results for the quarter ended in June - Earnings Summary
Brief: T2 Biosystems Announces Commercial Expansion Through Malaysia And Indonesia Distributor